Article thumbnail

Poor Regenerative Outcome after Skeletal Muscle Necrosis Induced by Bothrops asper Venom: Alterations in Microvasculature and Nerves

By Rosario Hernández, Carmen Cabalceta, Patricia Saravia-Otten, Alessandra Chaves, José María Gutiérrez and Alexandra Rucavado
Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (1989). A new muscle damaging toxin, myotoxin II, from the venom of the snake Bothrops asper (terciopelo).
  2. (2003). Acidente botro ´pico. In:
  3. (2002). Acute local nerve lesions induced by Bothrops jararacussu snake venom.
  4. (2002). Apoptosis and muscle fibre loss in neuromuscular disorders.
  5. (2001). Apoptosis in skeletal muscle.
  6. (1998). Apoptotic myonuclei in human Duchenne muscular dystrophy.
  7. (1972). Basal lamina: the scaffold for orderly cell replacement. Observations on regeneration of injured muscle fibers and capillaries.
  8. (2009). Calcium imaging of muscle cells treated with snake myotoxins reveals toxin synergism and presence of acceptors.
  9. (2004). Cellular and molecular regulation of muscle regeneration.
  10. (2008). Cellular pathology induced by snake venom phospholipase A2 myotoxins and neurotoxins: common aspects of their mechanisms of action.
  11. (1996). Clinical features of envenoming by snake bites.
  12. (1995). Clinical toxicology of snakebites
  13. (2002). Complications of Bothrops, Porthidium and Bothriechis snakebites in Colombia. A clinical and epidemiological study of 39 cases attended in a university hospital.
  14. (2006). Confronting the neglected problem of snake bite envenoming: the need for a global partnership.
  15. (1988). d’Albis A
  16. (2003). Efectos locales en el envenenamiento ofı ´dico en Ame ´rica Latina. In:
  17. (1992). Effects induced by bothropstoxin, a component from Bothrops jararacussu snake venom, on mouse and chick muscle preparations.
  18. (2009). Epidemiological, clinical and therapeutic aspects of Bothrops asper bites.
  19. (2005). Equivalent effects of snake PLA2 neurotoxins and lysophospholipid-fatty acid mixtures.
  20. (2009). Experimental pathology of local tissue damage induced by Bothrops asper snake venom.
  21. (2005). Fast’’ and ‘‘slow’’ muscle fibres in hindlimb muscles of adult rats regenerate from intrinsically different satellite cells.
  22. (1994). Hemorrhagic metalloproteinases from snake venoms.
  23. (2006). Human macrophages rescue myoblasts and myotubes from apoptosis through a set of adhesion molecular systems.
  24. (2008). Inflammation in skeletal muscle regeneration.
  25. (2008). Innervation of regenerating muscle.
  26. (1995). Isolation and characterization of a metalloproteinase with weak hemorrhagic activity from the venom of the snake Bothrops asper (Terciopelo).
  27. (2010). Isolation and characterization of a myotoxin from the venom of Macrovipera lebetina transmediterranea.
  28. (1995). Macrophage-released factor stimulates selectively myogenic cells in primary muscle culture.
  29. (2002). Macrophage-secreted myogenic factors: a promising tool for greatly enhancing the proliferative capacity of myoblasts in vitro and in vivo.
  30. (2006). Macrophages and skeletal muscle regeneration: a clodronate-containing liposome depletion study.
  31. (2005). Microvessel damage by B. jararacussu snake venom: pathogenesis and influence on muscle regeneration.
  32. (2010). Mun ˜oz-Ca ´noves P
  33. (1984). Muscle necrosis and regeneration after envenomation by Bothrops jararacussu snake venom.
  34. (1999). Muscle regeneration: molecular aspects and therapeutic implications.
  35. (2001). Myogenic satellite cells: physiology to molecular biology.
  36. (2003). Myotoxic phospholipases A2 and the regeneration of skeletal muscles.
  37. (2003). Neutrophils do not contribute to local tissue damage, but play a key role in skeletal muscle regeneration, in mice injected with Bothrops asper snake venom.
  38. (2006). Novel insights into capillary vessel basement membrane damage by snake venom hemorrhagic metalloproteinases: a biochemical and immunohistochemical study.
  39. (1998). Nu ´n ˜ez J, Gutie ´rrez JM
  40. (1997). Phospholipase A2 myotoxins from Bothrops snake venoms.
  41. (2001). Regeneration and change of muscle fiber types after injury induced by a hemorrhagic fraction isolated from Agkistrodon contortrix laticinctus.
  42. (2010). Regeneration of mammalian skeletal muscle. Basic mechanisms and clinical implications.
  43. (2009). Response and adaptation of skeletal muscle to denervation stress: the role of apoptosis in muscle loss.
  44. (2000). Rucavado A
  45. (2003). Skeletal muscle degeneration induced by venom phospholipases A2: insights into the mechanisms of local and systemic myotoxicity.
  46. (1995). Skeletal muscle necrosis and regeneration after injection of BaH1, a hemorrhagic metalloproteinase isolated from the venom of the snake Bothrops asper (terciopelo).
  47. (1984). Skeletal muscle regeneration after myonecrosis induced by crude venom and a myotoxin from the snake Bothrops asper (Fer-de-Lance).
  48. (2008). Skeletal Muscle Repair and Regeneration.
  49. (2010). Snakebite envenoming from a global perspective: Towards an integrated approach.
  50. (2004). Snakebites in Central and South America: Epidemiology, clinical features, and clinical management. In:
  51. (2005). Technical aspects of immunohistochemistry.
  52. (2008). The global burden of snakebite: a literature analysis and modelling based on regional estimates of envenoming and deaths.
  53. (1991). The use of Picrosirius-polarization method for the study of the biopathology of collagen.
  54. (2010). Tissue pathology induced by snake venoms: how to understand a complex pattern of alterations from a systems biology perspective?
  55. (1991). Towards understanding skeletal muscle regeneration.
  56. (2010). Understanding the in vitro neuromuscular activity of snake venom Lys49 phospholipase A2 homologues.
  57. (2007). World Health Organization